What is the elimination time of roflumilast in mice? 

The elimination time of roflumilast in mice, or its half-life, is not directly provided in the contexts of the research papers summarized above. However, insights into roflumilast's pharmacokinetics, effects, and mechanisms of action in various models can be gleaned from the provided abstracts, which indirectly inform about its metabolism and potential elimination characteristics in mice or other studied organisms. Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, has been extensively studied for its effects on cognitive functions, metabolic effects, and potential therapeutic applications in conditions such as Alzheimer's disease, sleep deprivation-induced cognitive dysfunction, obesity, alcohol use disorders, tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). These studies have demonstrated roflumilast's ability to enhance cAMP signaling, improve memory and cognitive functions, reduce body weight and adipogenesis, decrease ethanol intake and preference, and exhibit anti-inflammatory properties. While the specific elimination time in mice is not mentioned, the pharmacokinetics of roflumilast in humans, including its peak plasma concentration, volume of distribution, and elimination half-life, have been characterized. In humans, roflumilast shows a mean elimination half-life of approximately 15.70 hours, with its active metabolite, roflumilast N-oxide, having a slightly longer half-life. Although these parameters are specific to humans, they provide a basis for understanding roflumilast's metabolic processing and potential elimination timeline in mammals. Given the absence of direct data on the elimination time of roflumilast in mice within the provided contexts, one can infer that its pharmacokinetic profile would need to be extrapolated from human data or directly studied in mice to obtain accurate elimination times. The research underscores roflumilast's broad therapeutic potential and its complex metabolic and pharmacokinetic profile across different species and conditions.

Roflumilast increases bacterial load and dissemination in a model of pseudomononas aeruginosa airway infection

The elimination time of roflumilast in mice was not addressed in the paper.

Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice

Not addressed in the paper.

Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavailability

Not addressed in the paper.

The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.

Not addressed in the paper.

Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway.

Not addressed in the paper.

Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, Aβ extrusion transporter ABCB1, and reversal by PKA inhibitor H89

Not addressed in the paper.

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis

Not addressed in the paper.

The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.

Not addressed in the paper.

The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.

Not addressed in the paper.

Roflumilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Sleep Deprivation-Induced Cognitive Dysfunction in C57BL/6J Mice

The elimination time of roflumilast in mice was not specified in the provided abstract and title.